tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Biegler, 70 are a BUY (92.11%), 6 are a HOLD (7.89%).
Analyst Matthew Biegler works at OPPENHEIMER with a stock forecast success ratio of 25.56% fulfilled within 51.82 days on average.
Matthew Biegler’s has documented 140 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on FATE, Fate Therapeutics at 27-Feb-2024.
Analyst best performing recommendations are on CELU (CELULARITY).
The best stock recommendation documented was for CELU (CELULARITY) at 1/28/2022. The price target of $9 was fulfilled within 41 days with a profit of $4.74 (111.27%) receiving and performance score of 27.14.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Sell
6
$-0.71 (-10.58%)
4
19 days ago
1/3 (33.33%)
$-1.34 (-18.26%)
207
Hold
7
$0.29 (4.32%)
3
1 months 20 days ago
7/8 (87.5%)
$-0.46 (-6.17%)
153
Hold
1 months 20 days ago
7/12 (58.33%)
$48.8 (301.23%)
119
Buy
10
$3.29 (49.03%)
12
1 months 20 days ago
5/8 (62.5%)
$2.54 (34.05%)
87
Hold
7
$0.29 (4.32%)
6
1 months 20 days ago
3/6 (50%)
$-0.46 (-6.17%)
88
Which stock is Matthew Biegler is most bullish on?
Which stock is Matthew Biegler is most reserved on?
What Year was the first public recommendation made by Matthew Biegler?
